E
Eculizumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Patient Medication Guide
Physician Educational Material
Subsidy Information and Financing Scheme
No
Active ingredient: Eculizumab
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Eculizumab 300 mg concentrate for solution for infusion as monotherapy for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) in adults and children.
Funding status
[R] Eculizumab 300 mg concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 April 2026.
[R] Eculizumab should be used in line with the additional clinical criteria listed in the Annex.
[NR] MAF assistance does not apply to iptacopan or ravulizumab for treating PNH or aHUS.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Soliris Infusion, Solution Concentrate 300 mg/vial |
|